Table 2.
Summary of the breadth and potency of MAb neutralization against 178 HIV-1 Env pseudoviruses
| Virus clade | Titer (μg/ml) | Measured by IC50 |
Measured by IC80 |
||||
|---|---|---|---|---|---|---|---|
| VRC03a | VRC06 | VRC06b | VRC03a | VRC06 | VRC06b | ||
| All clades | <50 | 49% | 22% | 44% | 41% | 16% | 37% |
| (n = 178) | <1 | 35% | 10% | 28% | 24% | 3% | 20% |
| GMTb | 0.361 | 1.8 | 0.443 | 0.763 | 3.8 | 1.1 | |
| A | <50 | 56% | 37% | 56% | 41% | 30% | 41% |
| (n = 27) | <1 | 37% | 15% | 26% | 19% | 4% | 19% |
| GMT | 0.510 | 1.7 | 0.899 | 0.775 | 6.2 | 1.7 | |
| B | <50 | 79% | 39% | 74% | 71% | 26% | 66% |
| (n = 38) | <1 | 66% | 18% | 55% | 53% | 11% | 34% |
| GMT | 0.173 | 1.5 | 0.290 | 0.504 | 2.0 | 0.831 | |
| C | <50 | 48% | 19% | 44% | 35% | 11% | 31% |
| (n = 54) | <1 | 30% | 6% | 24% | 19% | 0% | 17% |
| GMT | 0.652 | 3.2 | 0.778 | 0.992 | 7.3 | 1.2 | |
| D | <50 | 22% | 11% | 11% | 11% | 0% | 11% |
| (n = 9) | <1 | 11% | 0% | 11% | 11% | 0% | 11% |
| GMT | 1.9 | 36.9 | 0.055 | 0.286 | >50 | 0.2 | |
| CRF01_AE | <50 | 25% | 6% | 13% | 25% | 6% | 13% |
| (n = 16) | <1 | 13% | 6% | 6% | 6% | 0% | 6% |
| GMT | 0.774 | 0.232 | 0.291 | 4.6 | 1.0 | 2.6 | |
| CRF02_AG | <50 | 19% | 13% | 25% | 19% | 13% | 25% |
| (n = 16) | <1 | 19% | 13% | 19% | 13% | 0% | 19% |
| GMT | 0.100 | 0.633 | 0.100 | 0.955 | 3.6 | 0.474 | |
| Other | <50 | 39% | 6% | 28% | 33% | 6% | 28% |
| (n = 18) | <1 | 33% | 6% | 22% | 17% | 0% | 17% |
| GMT | 0.313 | 0.305 | 0.224 | 0.770 | 2.4 | 1.4 | |
a
Data for VRC03 were published previously (47). However, the data used in this paper are from a completely independent experimental run and are consistent with those generated from the previous study.
b
Geometric mean titers (GMT) were calculated for neutralization-sensitive viruses with an IC50 or IC80 value of <50 μg/ml.